Linked Life Data

19104207

Source:http://linkedlifedata.com/resource/pubmed/id/19104207

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
1 Suppl
pubmed:dateCreated
2008-12-23
pubmed:abstractText
The successful translation of promising research findings from basic research laboratories into useful clinical products for the management of septic patients has proven to be a daunting challenge. The complexity and variability of the clinical entity referred to as sepsis makes it intrinsically difficult to model preclinical systems and predict efficacy of potentially useful, experimental, therapeutic agents. Technological innovations in microarrays, microfluidics, and nanotechnology make it feasible to study the evolution of sepsis in small animal models in considerable detail. The recognized limitations of standard preclinical platforms used to study sepsis have lead to innovative approaches to study sepsis in silico, and in more complex and clinically more valid ex vivo tissue perfusion models and animal systems. It is abundantly clear that sepsis researchers need to do a better job informing clinicians about the possible benefits and potential risks of new treatment interventions as they traverse the gap between the bench and the bedside.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
AIM
pubmed:status
MEDLINE
pubmed:month
Jan
pubmed:issn
1530-0293
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
37
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
S10-5
pubmed:meshHeading
pubmed:year
2009
pubmed:articleTitle
Translational research in the development of novel sepsis therapeutics: logical deductive reasoning or mission impossible?
pubmed:affiliation
Infectious Disease Division (SMO), Memorial Hospital of Rhode Island, Pawtucket, RI, USA. steven_opal@brown.edu
pubmed:publicationType
Journal Article